# Effect of Xenon on Brain Injury After Aneurysmal Subarachnoid Hemorrhage

Study · id `cardio:ct-nct04696523` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04696523](<https://clinicaltrials.gov/study/NCT04696523>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04696523

Browse, organ or system: Heart; Brain  
Browse, condition area: Stroke; Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 160 participants.

## Technical summary

Registry record NCT04696523. Randomized; double masking; primary purpose treatment. Start 2025-04-22 (actual); primary completion 2029-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 160 participants (planned count; ClinicalTrials.gov record NCT04696523, source copy `cardio:ctgov-nct04696523-2025-05-01`, retrieved 2026-10-26)
- Started: 2025-04-22 (actual) (ClinicalTrials.gov record NCT04696523, source copy `cardio:ctgov-nct04696523-2025-05-01`, retrieved 2026-10-26)
- Primary completion: 2029-12-31 (anticipated) (ClinicalTrials.gov record NCT04696523, source copy `cardio:ctgov-nct04696523-2025-05-01`, retrieved 2026-10-26)
- Completion: 2029-12-31 (anticipated) (ClinicalTrials.gov record NCT04696523, source copy `cardio:ctgov-nct04696523-2025-05-01`, retrieved 2026-10-26)
- Countries: Finland; Sweden (ClinicalTrials.gov record NCT04696523, source copy `cardio:ctgov-nct04696523-2025-05-01`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04696523-2025-05-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of Xenon on Brain Injury After Aneurysmal Subarachnoid Hemorrhage
- Acronym: Xe-SAH
- Condition: Subarachnoid Hemorrhage, Aneurysmal
- Condition: Cerebral Injury
- Condition: Cerebral Ischemia
- Condition: Cerebral Infarction
- Condition: Cardiac Event
- Condition: Cardiac Failure
- Intervention (Drug): Xenon
- Intervention (Drug): air/oxygen
- Lead sponsor: Turku University Hospital
- Lead sponsor class: OTHER\_GOV
- Collaborator: Academy of Finland
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Subarachnoid hemorrhage (`cardio:subarachnoid-hemorrhage`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Turku University Hospital (`cardio:org-turku-university-hospital`)

## Provenance

Content hash: 334a76f1345c447620cb2de78cfc81d82cfee5ae1665b1fac1d2028b9ecc0963
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
